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Abstract Because of its control of spike-timing and
oscillatory network activity, γ-aminobutyric acid (GABA)-
ergic inhibition is a key element in the central regulation of
somatic and mental functions. The recognition of GABAA
receptor diversity has provided molecular tags for the
analysis of distinct neuronal networks in the control of
specific pharmacological and physiological brain functions.
Neurons expressing α1GABAA receptors have been found
to mediate sedation, whereas those expressing α2GABAA
receptors mediate anxiolysis. Furthermore, associative
temporal and spatial memory can be regulated by modulat-
ing the activity of hippocampal pyramidal cells via
extrasynaptic α5GABAA receptors. In addition, neurons
expressing α3GABAA receptors are instrumental in the
processing of sensory motor information related to a
schizophrenia endophenotype. Finally, during the postnatal
development of the brain, the maturation of GABAergic
interneurons seems to provide the trigger for the experi-
ence-dependent plasticity of neurons in the visual cortex,
with α1GABAA receptors setting the time of onset of a
critical period of plasticity. Thus, particular neuronal
networks defined by respective GABAA receptor subtypes
can now be linked to the regulation of various clearly
defined behavioural patterns. These achievements are of
obvious relevance for the pharmacotherapy of certain
brain disorders, in particular sleep dysfunctions, anxiety
disorders, schizophrenia and diseases associated with
memory deficits.
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Inhibitory interneurons
The activity of inhibitory interneurons, most of which are
γ-aminobutyric acid (GABA)-ergic, is thought to set the
spatio-temporal conditions required for the various patterns
of network oscillations that may be critical for information
processing (O’Keefe and Nadel 1978; O’Keefe and Recce
1993; Skaggs et al. 1996; Paulsen and Moser 1998; Engel
et al. 2001; Harris et al. 2002; Mehta et al. 2002; Traub et
al. 2002; Klausberger et al. 2003).
Diversity of interneurons
To achieve a strict time control of principal cells,
GABAergic interneurons display several remarkable fea-
tures. (1) Their action potential is traditionally faster than
that of pyramidal cells and the kinetics of synaptic events
that excite inhibitory cells are faster than those that excite
pyramidal cells (Martina et al. 1998; Geiger et al. 1997). (2)
GABAergic interneurons are morphologically highly di-
verse, which reflects their multiple functions in neuronal
networks (Gupta et al. 2000; Markram et al. 2004; Monyer
and Markram 2004). (3) These interneurons show a
domain-specific innervation of principal cells; thus,
depending on the type of interneuron, particular input
domains of pyramidal cells can be selectively regulated
and, similarly, the output of pyramidal cells can be
specifically regulated by axo-axonic GABAergic
interneurons. (4) The response properties of interneuron
signalling is shaped by the type of GABAA receptor
expressed synaptically or extrasynaptically. For instance,
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the soma of hippocampal pyramidal cells is innervated by
two types of basket cells: the fast spiking parvalbumin-
containing basket cells form synapses containing α1GABAA
receptors, which display fast kinetics of deactivation (Nyíri
et al. 2001; Klausberger et al. 2002; Freund and Buzsaki
1996; Pawelzik et al. 2002), whereas the synapses of the
regular spiking cholecystokinin (CCK)-positive basket cells
contain α2GABAA receptors, which display slower kinetics
than α1 receptors (Nyíri et al. 2001; Brussaard and
Herbison 2000; Hutcheon et al. 2000; Jüttner et al. 2001;
Vicini et al. 2001). Axon initial segments of principal cells
also contain α2 receptors, which appear to be kinetically
sufficient for simple on/off signalling. Furthermore, distinct
GABAA receptors are segregated to synaptic and extra-
synaptic membranes (Nusser et al. 1998; Fritschy and
Brünig 2003). Thus, functionally specialized interneurons
operate with the kinetically appropriate GABAA receptor
subtypes to regulate network behaviour (Fig. 1, Table 1).
Since GABAergic interneurons are operative throughout
the brain, a highly diverse repertoire of GABAA receptors is
required.
Retrograde regulation of GABAergic interneurons
Retrograde signalling adds another level of complexity to
the regulation of interneuron activity. The terminals of
CCK-positive GABAergic basket cells in hippocampus and
amygdala contain CB1-cannabinoid receptors (Katona et al.
1999, 2001). These receptors mediate depolarisation-
induced suppression of inhibition (DSI) (Pitler and Alger
1994; Alger and Pitler 1995). This phenomenon is due to
endocannabinoids which emanate from the postsynaptic
cell and act as retrograde signal (Wilson and Nicoll 2001;
Maejima et al. 2001). The depolarization of hippocampal
pyramidal cells (Pitler and Alger, 1992) and of cerebellar
Purkinje cells (Llano et al. 1991) results in a transient
decrease in the release of GABA from inhibitory terminals
that contain CB1-receptors and synapse onto the depolar-
ized cells (Vincent and Marty, 1993; Pitler and Alger, 1994;
Alger and Pitler, 1995).Both the DSI in the hippocampus
(Wilson and Nicoll 2001; Maejima et al. 2001) and the
cerebellum (Kreitzer and Regehr 2001a,b) are the result of
activity-dependent de-novo synthesis and release of endo-
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Fig. 1 Representation of a GABAergic synapse depicting major
elements of signal transduction. GABAA receptors are heteromeric
membrane proteins linked by an as yet unknown mechanism to the
synaptic anchoring protein, gephyrin, and the cytoskeleton. The
sequence of subunits corresponds to a modelling proposal (Ernst et
al. 2003). The binding sites for GABA and benzodiazepines are
located at the interface of the α/β and α/γ2 subunits, respectively.
Synaptic GABAA receptors mediate phasic inhibition providing a
rapid point-to-point communication for synaptic integration and
control of rhythmic network activities. Extrasynaptic GABAA recep-
tors (not shown) are activated by synaptic spillover or the non-
vesicular release of GABA. By mediating tonic inhibition, they
provide a maintenance level of reduction in neuronal excitability
(Mody and Pearce 2004; Möhler et al. 2005)
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cannabinoids from the postsynaptic neuron. By interacting
with CB1 receptors, the calcium influx into the presynaptic
terminal is reduced (Kreitzer and Regehr 2001a; Caulfield
and Brown 1992) resulting in a decrease of GABA release.
Pharmacologically, the inhibition of the degradation of
anandamide resulted in an CB1 receptor-mediated anxio-
lytic response (Kathuria et al. 2003). Recently, endocanna-
binoids were shown to mediate not only transient, but also
long term changes in inhibitory synaptic transmission.
Endocannabinoid production, stimulated through metabo-
tropic glutamate receptor activation in hippocampal pyra-
midal cells, caused a long lasting reduction in GABAergic
signaling onto the pyramidal cells (Chevaleyre and Castillo
2003). A similar change in long-term synaptic plasticity of
Table 1 GABAA-receptor subtypes (compiled from Möhler et al. 2002; Fritschy and Brünig 2003)
Composition Pharmacological characteristics Regional and neuronal localisation Subcellular localization
α1β2γ2 Major subtype (60 % of all GABAA
receptors). Mediates the sedative,
amnestic and, to a large extent, the
anticonvulsant action of benzodiazepine
site agonists. High affinity for classical
benzodiazepines, zolpidem and the
antagonist flumazenil
Cerebral cortex (layer 1–VI, selected
interneurons and principal cells);
hippocampus (selected interneurons
and principal cells); pallidum striatum
(interneurons); thalamic relay nuclei;
olfactory bulb (mitral cells and
interneurons); cerebellum (Purkinje
cells and granule cells); deep cerebellar
nuclei; amygdala; basal forebrain;
substantia nigra pars reticulata; inferior
colliculus; brainstem
Synaptic (soma and dendrites)
and extrasynaptic in all neurons
with high expression
α2β3 γ2 Minor subtype (15–20%). Mediates
anxiolytic action of benzodiazepine site
agonists. High affinity for classical
benzodiazepine agonists and the
antagonist flumazenil. Intermediate
affinity for zolpidem
Cerebral cortex (layers I–IV)
hippocampal formation (principal cells
mainly on the axon initial segment);
olfactory bulb (granule cells); striatum
(spiny stellate cells); inferior olivary
neurons (mainly on dendrites);
hypothalamus; amygdala (principal
cells); superior colliculus; motor
neurons
Mainly synaptic, enriched in axon
initial segment of cortical and
hippocampal pyramidal cells
α3βnγ2 Minor subtype (10–15%). High affinity
for classical benzo-diazepine agonists
and the antagonist flumazenil.
Intermediate affinity for zolpidem
Cerebral cortex (principal cells in
particular in layers V and VI; some axon
initial segments); hippocampus (some
hilar cells); olfactory bulb (tufted cells);
thalamic reticular neurons; cerebellum
(Golgi type II cells); medullary reticular
formation; inferior olivary neurons;
amygdala; superior colliculus;
brainstem; spinal cord; medial septum;
basal forebrain cholinergic neurons;
raphe and locus coeruleus
(serotoninergic and catecholaminergic
neurons)
Mainly synaptic, including some
axon initial segments;
extrasynaptic in inferior olivary
neurons
α4βnδ Less than 5 % of all receptors.
Insensitive to classical benzodiazepine
agonists and zolpidem
Dentate gyrus (granule cells); thalamus Extrasynaptic (no direct
morphological evidence)
α5β3γ2 Less than 5% of all receptors; high
affinity for classical benzodiazepine
agonists and the antagonist flumazenil.
Low affinity for zolpidem
Hippocampus (pyramidal cells);
olfactory bulb (granule cells,
periplomerular cells); cerebral cortex;
amygdala; hypothalamus; superior
colliculus; superior olivary neurons;
spinal trigeminal neurons; spinal cord
Extrasynaptic in hippocampus,
cerebral cortex, and olfactory
bulb; synaptic and extrasynaptic
in spinal trigeminal nucleus and
superior olivary nucleus
α6β2,3γ2 Less than 5 % of all receptors.
Insensitive to classical α6β2,3δ
benzodiazepine agonists and zolpidem.
Minor population. Lacks
benzodiazepine site
Cerebellum (granule cells); dorsal
cochlear nucleus
Synaptic (cerebellar glomeruli)
and extrasynaptic on granule
cell dendrites and soma
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the GABAergic system was observed in the amygdala. The
release of endocannabinoids in the basolateral amygdala
contributed to the extinction of aversive memory based on a
long lasting decrease of GABAergic signalling (Marsicano
et al. 2002). Thus, CB1 receptor activation in the
hippocampus, amygdala and possibly other parts of the
brain result in reduced levels of anxiety. This is due to
either a transient depression of GABA release or a
modulation of long term plasticity at the respective
synapses. In addition, endocannabinoids act as retrograde
signals at excitatory glutamatergic synapses where they
mediate a depolarisation-induced suppression of excitation
(Kreitzer and Regehr 2001a) which may also contribute to
their behavioral effects.
Structure of GABAA receptors
Like other members of the nicotinic superfamily of
ligand-gated ion channels, ionotropic GABA receptors
are considered to consist of 5 protein subunits arranged
around a central pore that constitutes the actual ion
channel. Each subunit has a large extracellular N-terminal
domain which incorporates part of the agonist/antagonist
binding site, followed by three membrane spanning
domains (M1-3), an intracellular loop of variable length
and a fourth membrane spanning domain (M4), with the
C-terminal end being extracellular. Each subunit arranges
itself such that the second membrane-spanning domain
(M2) forms the wall of the channel pore. The cytoplasmic
loop, between the third and fourth transmembrane
domains (M3 and M4), is believed to be the target for
protein kinases, required for subcellular targeting and
membrane clustering of the receptor. There are 16
different subunits comprising the GABAA receptor family:
α1–6, β1–3, γ1–3, δ, ɛ, π and θ. In addition, there are splice
variants of many of these subunits. Based on this subunit
repertoire more than 2000 different GABAA receptors
could exist if the subunit combinations were restricted to
those containing two α, two β and one other subunit. In
fact, studies of native GABAA receptors suggest that there
may be less than 20 widely occurring GABAA receptor
subtype combinations, with the major combinations being
α1β2/3γ2, α2β3γ2, α3β3γ2 (for review Barnard et al.
1998; Whiting et al. 2000; Sieghart and Sperk 2002;
Möhler et al. 2000, 2002, 2005; Möhler 2001, 2002;
Fritschy et al. 2004; Rudolph and Möhler 2006) (Table 1).
In the retina homomeric receptors consisting of the ρ
subunit represent a particular class of GABA gated chloride
channels. Their GABA site is insensitive to bicuculline and
baclofen and they are not modulated by barbiturates or
benzodiazepines. Due to these distinctive features the
receptors are sometimes termed GABAc-receptors
(Bormann 2000), although they are a homomeric class of
GABAA-receptors (Barnard et al. 1998).
The physiological significance of the structural diversity
of GABAA receptors lies in the provision functionally
diverse of receptors which differ in their channel kinetics,
affinity for GABA, rate of desensitization and ability for
transient chemical modification such as phosphorylation. In
addition, GABAA receptor subtypes differ in their topology
in neuronal networks in that they show a cell-type specific
expression and-in case of multiple receptor subtypes
present in a neuron-a domain-specific location (Table 1).
Pharmacology of GABAA receptors
Diazepam-sensitive GABAA receptors
Receptors containing the α1, α2, α3 or α5 subunits in
combination with any of the β subunits and the γ2 subunit
are most prevalent in the brain. These receptors are
sensitive to benzodiazepine modulation. The major receptor
subtype is assembled from the subunits α1β2γ2, with only a
few brain regions lacking this receptor (e.g. granule cell
layer of the olfactory bulb, reticular nucleus of the
thalamus, spinal cord motoneurons) (Fritschy and Mohler
1995; Pirker et al. 2000, Fritschy and Brünig 2003).
Receptors containing the α2 or α3subunit are consider-
ably less abundant and are highly expressed in brain areas
where the α1 subunit is absent or present at low levels. The
α2 and α3 subunits are frequently coexpressed with the β3
and γ2 subunits which is particularly evident in hippocam-
pal pyramidal neurons (α2β3γ2) and in cholinergic neurons
of the basal forebrain (α3β3γ2). The α3 GABAA receptors
are the main subtypes expressed in monoaminergic and
basal forebrain cholinergic cells (Gao et al. 1993) and are,
in addition, strategically located in the thalamic reticular
nucleus for modulating the thalamo-cortical circuit
(Huntsmann et al. 1999). Marked differences in desensiti-
zation kinetics have been reported between synaptic α2-and
extrasynaptic α3-receptors whereby the latter desensitize
very slowly (Devor et al. 2001). The factors regulating
GABAA receptor kinetics at synaptic and extrasynaptic
sites are yet unknown (Moss and Smart 2001). The ligand-
binding profile of the α2-and α3-receptors differs from that
of α1β2γ2 by having a considerably lower displacing
potency for ligands such as βCCM, CL 218,872, and
zolpidem.
Receptors containing the α5 subunit are of minor
abundance in the brain but are expressed to a significant
extent in the hippocampus, where they comprise 15 % to 20
% of the diazepam-sensitive GABAA receptor population,
predominately coassembled with the β3 and γ2 subunits.
Pharmacologically, the α5-receptors are differentiated from
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α1β2γ2, α2β3γ2 and α3β3γ2 receptors by a lower affinity
to CL 218, 872 and near-insensitivity to zolpidem.
The subunits γ1 and γ3 characterize a small population
of receptors that contain various types of α and β subunits.
Due to their reduced affinity for the classical benzodiaze-
pines they do not appear to contribute to any great extent to
their pharmacology in vivo.
It should be kept in mind that complex benzodiazepine
actions such as the development of tolerance can implicate
more than a single receptor subtype. For instance, while the
sedative action of diazepam is mediated by α1 GABAA
receptors (see below), the development of tolerance to this
action under chronic diazepam treatment requires the
interaction with both α1 GABAA receptors and α5 GABAA
receptors (van Rijnsoever et al. 2004).
Diazepam-insensitive GABAA receptors
GABAA receptors that do not respond to clinically used
ligands such as diazepam, flunitrazepam, clonazepam, and
zolpidem are of low abundance in the brain and are largely
characterized by the α4 and α6 subunits. Receptors contain-
ing the α4 subunit are generally expressed at very low
abundance but more prominently in thalamus and dentate
gyrus (Pirker et al. 2000); those containing the α6 subunit
are restricted to the granule cell layer of the cerebellum
(about 30–50 % of all GABAA receptors in the cerebellum;
Nusser et al. 1996; Pöltl et al. 2003). Both receptor
populations are structurally heterogeneous, and the majority
of the α6-containing receptors contain the γ2 subunit in the
α6α1β2γ2 subunit combination (Pöltl et al. 2003). Apart
form the lack of affinity of classical benzodiazepines, the
benzodiazepine-site profile of α4 and α6 receptors is
characterized by a low affinity for flumazenil and bretazenil
and an agonistic efficacy of Ro 15-4513 and bretazenil
(Benson et al. 1998). The δ subunit is frequently coas-
sembled with the α4 or the α6 subunit in benzodiazepine
insensitive receptors (Möhler et al. 2000; Whiting et al.
2000; Möhler 2001). Receptors containing the δ subunit are
located exclusively at extrasynaptic sites as shown in dentate
gyrus and cerebellum. They are tailor made for tonic
inhibition, due to their high affinity for GABA and slow
desensitization kinetics (Brickley et al. 1996, 2001).
GABAA receptor subtypes: a new pharmacology
The selective pattern of expression of GABAA receptor
subtypes opened the possibility to modulate distinct
neuronal circuits, provided novel ligands were found which
displayed a differential interaction with GABAA receptor
subtypes based on either selective affinity or selective
efficacy (Table 2). Such agents would be expected to
display therapeutic indications which are more selective
than those of the classical benzodiazepines and go beyond
their spectrum of activity.
The dissection of receptor pharmacology has been
achieved experimentally by generating four lines of point-
mutated mice in which the receptors containing the α1, α2,
α3 or α5 subunits, respectively, are rendered diazepam-
insensitive by replacing a conserved histidine residue (H) in
the drug-binding domain by an arginine (R; Benson et al.
1998; Rudolph et al. 1999; Löw et al. 2000; Crestani et al.
2002). In the respective point-mutated mice, the pharmaco-
logical action linked to the point-mutated receptor should be
missing and thereby reveal the pharmacological relevance of
the respective receptor in wild-type mice. Since the subunit
composition and distribution of GABAA receptor subtypes
are largely conserved between rodents and non-human
primates, the results are thought to be relevant to the human
condition (Rudolph and Möhler 2004).
GABAA receptors for sedation and sleep
Frequently, sedation is taken as a surrogate marker for
hypnotic activity. The sedative component of benzodiaze-
pines, measured by the reduction of locomotor activity, has
been attributed to neuronal circuits expressing α1GABAA
receptors, the most prevalent receptor subtype in the brain.
Mice in which the α1GABAA receptor has been rendered
diazepam-insensitive by a point mutation [α1(H101R)] fail
to be sedated by diazepam (Rudolph et al. 1999; McKernan
et al. 2000). Ligands with a preferential affinity for α1
receptors such as zolpidem or zaleplon are used as
hypnotics (Table 2). Similarly, the changes in the electro-
encephalogram (EEG) pattern induced by zolpidem in wild-
type mice are almost exclusively mediated via α1GABAA
receptors (Kopp et al. 2004a). However, the changes in
sleep architecture (suppression of rapid eye movement or
REM sleep) and EEG-frequency profiles (reduction of
slow-wave sleep, increase in fast β-frequencies) induced
by classical benzodiazepines are largely attributable to
effects mediated by receptors others than α1 (Tobler et al.
2001). The enhancement of α2GABAA receptors by
diazepam appears to have the most pronounced effect on
the sleep EEG in wild-type mice. When the α2GABAA
receptor is rendered diazepam-insensitive by a point
mutation [α2(H101R)], the diazepam-induced suppression
of δ-waves, the increase in fast β-waves in non-REM sleep
(>16 Hz) and the diazepam-induced increase of θ-waves in
REM sleep are strongly attenuated (Kopp et al. 2004b).
Thus, the hypnotic EEG fingerprint of diazepam can be
dissociated from its sedative action. Future hypnotics might
target changes in the EEG pattern, which are characteristic
of physiological sleep, and thereby aim at improving sleep
quality. For instance, the GABA-mimetic gaboxadol
(4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-3-0l hydrochlo-
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ride; synonym THIP), which interacts preferentially with
α4β3δ GABAA receptors in vitro (Brown et al. 2002;
Storustovu and Ebert 2003) has been found to enhance
slow-wave sleep in vivo (Lancel and Steiger 1999; Huckle
2004).
GABAA receptors for anxiolytic action
Since α1GABAA receptors were found to mediate sedation
but not anxiolysis (Rudolph et al. 1999; McKernan et al.
2000), the anxiolytic activity of benzodiazepines was
expected to reside in one or several of the remaining
benzodiazepine-sensitive GABAA receptors (α2, α3, α5).
The differentiation of GABAA receptors by knock-in point
mutations showed that the α2 receptor, but not the α3 or
α5GABAA receptor, mediated the anxiolytic activity of
diazepam (Löw et al. 2000; Crestani et al. 2002). In
α2(H101R) mice, but not in α3(H126R) or α5(H105R)
mice, diazepam failed to induce anxiolytic activity (light-
dark paradigm, elevated plus maze). With respect to the
α2GABAA receptor, a highly selective target for the
anxiolytic activity of benzodiazepine tranquillizers had
Table 2 GABAA receptor subtype ligands*
Drug Main activity Interaction with recombinant GABAA
receptors1,2
Reference
A.Benzodiazepine site ligands
Zolpidem Hypnotic Preferential affinity for α1 Dämgen and Lüddens,
1999
Zaleplone Hypnotic Preferential affinity for α1 Dämgen and Lüddens,
1999
Indiplon Hypnotic Preferential affinity for α1 Foster et al. 2004
L-838 417 Anxiolytic Comparable affinity at α1, α2, α3, α5 subtype.
Partial agonist at α2, α3, α5 (not α1) subtype
McKernan et al. 2000
Ocinaplon Anxiolytic Comparable affinity at α1 α2, α3, α5 subtype.
Partial agonist at α2, α3, α5 subtype nearly
full agonist at α1
Lippa et al. 2005
SL 651 498 Anxiolytic Agonist at α2, α3, partial agonist at α1 and
α5 subtype
Griebel et al. 2003
TPA 023 Anxiolytic Partial agonist at α2, α3 subtypes, antagonist
at α1, α5 subtypes
Atack et al. 2006a
TPA 003 Anxiolytic Partial agonist at α3 subtype Dias et al. 2005
ELB 139 Anxiolytic Selective receptor profile uncertain Langen et al. 2005
L-655 708 Memory enhancer, Anxiogenic Partial inverse agonist with preference for
α5 subtype
Sternfeld et al. 2004;
Chambers et al. 2004;
Navarro et al. 2002,
2004
α3 IA Anxiogenic Weak inverse agonist at α3 Atack et al. 2005
B. Modulatory site other than
benzodiazepine site
Ethanol Anxiolytic Sedative High sensitivity (≥3 mM) at α4(α6)β3δ3;
Medium sensitivity (≥30 mM) at α4(α6)β2δ3;
Low sensitivity (≥100 mM) at α4(α6)β3γ2
Wallner et al. 2003
Neurosteroids (e.g. 3α,
5α-THDOC)
Anxiolytic Sedative Anaesthetic High sensitivity at δ-containing subtypes 3 and
at α1, α3 receptors in combination with β1
Belelli and Lambert 2005
Intravenous anaesthetics
(Etomidate Propofol)
Sedative Anaesthetic Act on receptor subtypes containing β3 i.e.
mainly α2 and α3 subtypes
Rudolph and Antkowiak
2004
C. GABA site
Gaboxadol Hypnotic Partial agonist at α1, α3 subtypes full agonist
at α5 and superagonist at α4β3δ receptors
2
Stornstovu and Ebert
2003
*This table is a modified version from Rudolph and Möhler (2006)
1Classical partial agonists that do not differentiate between GABAA receptor subtypes such as Bretazenil (Haefely et al. 1990) or Pagoclone
(Atack et al. 2006b) are not considered in this review.
2Data should be treated with caution as properties of recombinant receptors that are expressed in foreign host cells might not give an accurate
reflection of their neuronal counterparts.
3GABA is a weak partial agonist on δ-containing receptors, which largely explains the strong modulatory response of ligands acting on
δ-containing receptors (Bianchi and MacDonald 2003). THDOC, 5α-pregnane3α,21-diol-20-one.
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been identified. In keeping with this notion, the benzodi-
azepine site ligand L-838417, which exhibited efficacy at
α2, α3 and α5 but not α1GABAA receptors, proved to be
anxiolytic in wild-type rats (Table 2; McKernan et al.
2000). Similarly, partial agonists of 3-heteroaryl-2-pyri-
dones acting at the benzodiazepine site with efficacy at α2,
α3 and α5 receptors, but not at α1 receptors, were found to
show anxiolytic activity in rodents (Table 2; Collins et al.
2002). Nevertheless, the extent to which the α3GABAA
receptor component contributed to the anxiolytic activity of
these ligands remained to be clarified. In mice that lacked
α3GABAA receptors, the anxiolytic activity of diazepam
was undiminished (Yee et al. 2005). However, an α3-
selective inverse agonist was anxiogenic and proconvulsant
in rodents (Table 2; Collins et al. 2002). In addition, TP003
with selective efficacy at the α3GABAA receptor was
anxiolytic, although only at high receptor occupancy (Dias
et al. 2005). Classical benzodiazepines exert anxiolysis at
low receptor occupancy suggesting that the α2GABAA
receptors, and not the α3GABAA receptors, are the major
mediators of this activity. The contribution of α3GABAA
receptors is unlikely to be of major relevance. Thus, the
strategy to develop novel daytime anxiolytics, which are
free of sedation, is clear (Whiting 2003; Möhler et al. 2002;
Möhler et al. 2005).
The α2GABAA receptors by their preponderant locali-
zation on the axon-initial segment of principal cells in the
cerebral cortex and hippocampus can control the output of
these cells. In addition, among α1, α2 and α3GABAA
receptors, α2 receptors are prominent in the central nucleus
of the amygdala, a key area for the control of emotions,
whereas α1GABAA receptors are totally absent (Marowsky
et al. 2004). Thus, by their strategic distribution in brain
areas involved in anxiety responses, α2GABAA receptors
represent key substrates for anxiolytic drug action.
GABAA receptors for learning and memory
Hippocampal pyramidal cells express various structurally
diverse GABAA receptors in a domain-specific manner.
Whereas α1 and α2GABAA receptors are largely synaptic,
α5GABAA receptors are located extrasynaptically at the
base of the spines and on the adjacent shaft of the
pyramidal cell dendrite. The α5GABAA receptors are
therefore in a privileged position to modulate the excitatory
input arising at the spines via N-methyl-D-aspartate
(NMDA) receptors. The introduction of a point mutation
(H105R) into the α5 subunit is associated with a specific
reduction of the hippocampal α5-subunit-containing
GABAA receptors, whereas the pattern of distribution is
undisturbed (Crestani et al. 2002). Mice with a partial
deficit of α5GABAA receptors in the hippocampus show an
improved performance in trace fear conditioning, a hippo-
campus-dependent memory task (Crestani et al. 2002). In
addition, these mutants display a resistance to the extinction
of conditional fear over several days (Yee et al. 2004).
Similarly, in a mouse line in which α5GABAA receptors are
absent in the entire brain (Collinson et al. 2002; Whiting
2003), improved performance has been observed in the
water maze model of spatial learning. Furthermore, a partial
inverse agonist acting at α5GABAA receptors enhances the
performance of wild-type rats in the water maze test
(Chambers et al. 2003; Table 2). Thus, neuronal inhibition
in the hippocampus mediated via α5GABAA receptors is a
critical element in the regulation of the acquisition and
expression of associative memory. Of note, the behavioural
consequences of an impairment of α5GABAA receptors are
opposite to those of an NMDA receptor deficit as shown in
spatial and temporal associative memory tasks. Thus, these
two receptor systems seem to play a complementary role in
controlling signal transduction at the hippocampal principal
cells.
GABAA receptors for sensorimotor processing
A deficit in GABAergic inhibitory control is one of the major
hypothesis underlying the symptomatology of schizophrenia
(Lewis et al. 2005). A potential contribution of GABAA
receptor subtypes has therefore been investigated with
regard to the overactivity of the dopaminergic system, an
overactivity considered to be a major factor in schizophre-
nia. The dopaminergic system is under GABAergic
inhibitory control mainly via α3-containing GABAA recep-
tors (Fritschy and Möhler 1995; Pirker et al. 2000). Their
functional role has been explored in mice lacking the α3
subunit gene. Mice with an α3-knockout display no
adaptive changes in the expression of α1, α2 and α5
subunits and their anxiety-related behaviour is normal.
However, they exhibit a marked deficit in prepulse
inhibition of the acoustic startle reflex, pointing to a deficit
in sensorimotor information processing (Yee et al. 2005).
This deficit in prepulse inhibition is normalized by the
administration of the antipsychotic dopamine D2-receptor
antagonist haloperidol, suggesting that the behavioural
phenotype is caused by hyperdopaminergia (Yee et al.
2005). Attenuation of prepulse inhibition is a frequent
phenotype of psychiatric conditions, including schizophre-
nia. These results suggest that α3-selective agonists might
constitute an effective treatment for sensorimotor gating
deficits in various psychiatric conditions, a view supported
by the observation that the partial benzodiazepine-site
agonist bretazenil, in earlier open clinical trials, displayed
an antipsychotic activity similar to neuroleptic drugs (Delini-
Stula and Berdah Tordjman 1996). The α3-selective agonists
might lack the sedative or extrapyramidal side-effects of
classical neuroleptics and would thus be valuable agents.
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Among various brain structures, the hippocampus is
believed to play an important role in the modulation of
prepulse inhibition. In α5(H105R) point-mutated mice, the
expression of the α5 subunit containing GABAA receptors
in the hippocampus is reduced (see above; Crestani et al.
2002). In these animals, prepulse inhibition is attenuated
concomitant with an increase in spontaneous locomotor
activity (Hauser et al. 2005). Thus, the α5-subunit-contain-
ing GABAA receptors, which are located extrasynaptically
and are thought to mediate tonic inhibition, are important
regulators of the expression of prepulse inhibition and
locomotor exploration. Post-mortem analyses of brains
from patients with schizophrenia have consistently revealed
structural abnormalities of developmental origin in the
hippocampus (Lewis et al. 2005). Such abnormalities may
include disturbances of α5GABAA receptor function given
that schizophrenic patients are known to exhibit a deficit in
prepulse inhibition. Thus, agonists acting on both α3 and
α5GABAA receptors may be beneficial in overcoming this
endophenotypic manifestation of the disease.
GABAA receptors for anaesthetic action
The targets that mediate the clinical effects of general
anaesthetics are largely unknown (Campagna et al. 2003;
Rudolph and Antkowiak 2004). Recent work has focused
on the role of GABAA receptors, with studies being based
on the analysis of point-mutated knock-in mice carrying
point mutations in the β3 and β2 subunits of the GABAA
receptor. These mutations render the GABAA receptors
containing the respective subunits insensitive to modulation
by etomidate, propofol and certain volatile anaesthetics,
such as enflurane. The β3-containing GABAA receptors
have been found to mediate the immobilizing action of
etomidate and propofol apparently in full (Table 2; Jurd et
al. 2003) and of enflurane, isoflurane and halothane in part
(Jurd et al. 2003; Lambert et al. 2005; Liao et al. 2005). In
addition, they mediate part of the hypnotic action of
etomidate and propofol (Jurd et al. 2003) but apparently
not of the volatile anaesthetics (Jurd et al. 2003; Lambert et
al. 2005). In contrast, the hypnotic action of etomidate is
mediated by β2-containing GABAA receptors (Reynolds et
al. 2003). Further studies have revealed that the respiratory
depressant action of etomidate and propofol is also
mediated by β3-containing GABAA receptors, whereas the
heart-rate depressant action and, to a large part, the
hypothermic action of etomidate and propofol are mediated
by other targets (Zeller et al. 2005; Cirone et al. 2004).
Thus, a β3-selective agent would be predicted to be
immobilizing and respiratory depressant but would largely
lack the heart-rate depressant and hypothermic actions of
etomidate and propofol. The analysis of α subunits
involved in mediating the actions of general anaesthetics
is expected to result in further insights into the contribution
of GABAA receptors to anaesthesia. Mutations in α
subunits have been identified in recombinant studies that
render αxβxγ2 GABAA receptors insensitive to specific
volatile anaesthetics but not to etomidate or propofol
(Mihic et al. 1997; Krasowski et al. 1998). Studies with
knock-in mice carrying these mutations are expected to
yield information as to the contribution of individual
GABAA receptors subtypes and the GABAA receptor
family as a whole to the action of volatile general
anaesthetics.
GABAA receptors controlling postnatal development
Apart from its trophic role in embryonal development
(Represa and Ben-Ari 2005), GABA is a major determinant
for postnatal developmental plasticity; this has been
investigated in various sensory systems. For instance, in
the rodent somatosensory system, axons from each whisker
form a somatotopic map in the cortex, known as the barrel
map. During a critical period of neonatal development, this
barrel map is fine-tuned in response to sensory experience
based on a variety of synaptic mechanisms involving not
only excitatory, but also inhibitory circuits (Foeller and
Feldmann 2004). The role of inhibitory circuits in synaptic
reorganization is similarly apparent in the auditory system.
Recent work has revealed a dramatic remodelling of
inhibitory synapses shortly after the onset of hearing (aural
dominance bands). The restructuring relies on both spon-
taneous and sensory-evoked neural activity (Kandler 2004).
In the postnatal visual system, the role of GABA has been
investigated in detail.
In the visual system, developmental plasticity is most
apparent in the formation of ocular dominance columns in
layer IV of the primary visual cortex. Cortical territories
receiving neuronal input from one eye alternate with
territories from the other eye. Initially, at birth, the thalamic
inputs from both eyes to the visual cortex are totally
overlapping (Ferster 2004). The separation of the visual
inputs into ocular dominance columns only arises in the
subsequent phase of remodeling. This process is sensitive
to light as shown by classical work on the influence of
monocular deprivation on ocular dominance plasticity
(Wiesel and Hubel 1963). After the closure of one eye
during a critical period of early postnatal life, the input
from the open eye subsequently has a larger cortical
territory than the input from the deprived eye. Critical
period plasticity is best viewed as a continuum of local
circuit computations that result in a structural rewiring of
thalamic afferents (Hensch 2005).
The mechanism of visual cortical plasticity was analyzed
in detail with regard to the contribution of intracortical
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GABAergic transmission. GABAergic transmission was
modulated locally by infusion of the benzodiazepine
agonist diazepam or the inverse agonist DMCM. Following
chronic infusion of diazepam into the striate cortex (starting
at postnatal days 14–17), the spacing of the ocular columns
was widened, whereas infusion of DMCM reduced the
spacing (Hensch and Stryker 2004). Visual responsiveness
remained undisturbed under these conditions (Hensch and
Stryker 2004). Thus, intracortical GABA interneurons
shape the geometry of the incoming thalamic arbours. In
addition, the degree of GABAergic inhibition has been
found to be a key determinant for the onset of critical
period plasticity. The enhancement of GABA transmission
by diazepam has long been known to induce the
premature onset of the critical period (Fagiolini and
Hensch 2000). It has now been found that only circuits
containing α1GABAA receptors drive cortical plasticity,
whereas α2-enriched connections separately regulate neu-
ronal firing (Fagiolini et al. 2004). These results are based
on the use of knock-in mice in which the respective
individual α-subunit had been rendered diazepam-insen-
sitive by a point mutation (Rudolph et al. 1999; Löw et al.
2000). These recent findings therefore present a cellular
and molecular basis for critical period plasticity in the
visual cortex triggered by neuronal inhibition (Fagiolini et
al. 2004; Ferster 2004).
For ocular stripes to form postnatally, activity in nearby
inputs from the same eye are considered to cooperate with
each other as cluster of cortical cells in their bid to take
over cortical territory (Ferster 2004). By lateral GABAergic
inhibitory connections, activity in more distant cells must
be “anti-correlated”. Inputs from the same eye are therefore
suppressed in their bid to take over the adjacent territories.
The pattern of ocular dominance columns thus arises during
the segregation of eye-specific inputs to the visual cortex in
a self-organizing process. The cortex itself, through a
specific type of GABAergic interneuron, plays a central
role in organizing this pattern (Ferster 2004). The special
developmental function of neocortical α1GABAA receptors
suggests that constraints should be placed on drugs
designated for use in human infants (Fagiolini et al. 2004).
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